Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.

ABSTRACT: Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (

SUBMITTER: Beckabir W 

PROVIDER: S-EPMC11126571 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature